Literature DB >> 18264121

Gabapentin evoked changes in functional activity in nociceptive regions in the brain of the anaesthetized rat: an fMRI study.

R J M Governo1, P G Morris, C A Marsden, V Chapman.   

Abstract

BACKGROUND AND
PURPOSE: Gabapentin (GBP; 1-(aminomethyl)cyclohexane acetic acid) is used clinically in the treatment of pain. Nevertheless, the sites and mechanisms of action of GBP are poorly defined. Herein, the effects of GBP on brain activation have been studied. EXPERIMENTAL APPROACH: Changes in blood oxygen level dependent (BOLD) haemodynamic signal following intravenous infusion of GBP (equivalent to 30 mg kg(-1) p.o., followed by 100 mg kg(-1) p.o.), compared to saline control, were studied in isofluorane anaesthetized rats (n=8 per group). Effects of GBP on mean arterial blood pressure (MAP) were also recorded.
RESULTS: Random effect analysis revealed that the lower dose of GBP produced significant (P<0.001) increases in BOLD signal intensity in several brain regions, including the thalamus and periaqueductal grey (PAG), compared to basal. This dose of GBP also produced significant (P<0.001) decreases in BOLD signal intensity in the amygdala and the entorhinal cortex. Increasing the dose of GBP (100 mg kg(-1)) produced significantly greater changes in BOLD signal intensity in several brain regions including the thalamus and PAG. MAP was not significantly altered by GBP, compared to saline. CONCLUSIONS AND IMPLICATIONS: GBP had marked positive and negative effects on BOLD signal intensity in a number of brain regions in naïve rats. The activation of key areas involved in nociceptive processing indicate a supraspinal site of action of GBP and this may contribute to its well-described analgesic effects in animal models of pain and clinical studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264121      PMCID: PMC2437921          DOI: 10.1038/bjp.2008.27

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  76 in total

1.  Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats.

Authors:  V Chapman; R Suzuki; H L Chamarette; L J Rygh; A H Dickenson
Journal:  Pain       Date:  1998-04       Impact factor: 6.961

2.  Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat.

Authors:  T Yamamoto; Y Sakashita
Journal:  Brain Res       Date:  1998-06-01       Impact factor: 3.252

3.  Analysis of fMRI time-series revisited--again.

Authors:  K J Worsley; K J Friston
Journal:  Neuroimage       Date:  1995-09       Impact factor: 6.556

4.  Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.

Authors:  M J Field; S McCleary; J Hughes; L Singh
Journal:  Pain       Date:  1999-03       Impact factor: 6.961

5.  Saturable transport of gabapentin at the blood-brain barrier.

Authors:  M S Luer; C Hamani; M Dujovny; B Gidal; M Cwik; K Deyo; J H Fischer
Journal:  Neurol Res       Date:  1999-09       Impact factor: 2.448

6.  The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat.

Authors:  J H Jun; T L Yaksh
Journal:  Anesth Analg       Date:  1998-02       Impact factor: 5.108

7.  Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI.

Authors:  A L Dixon; M Prior; P M Morris; Y B Shah; M H Joseph; A M J Young
Journal:  Neuropharmacology       Date:  2004-12-24       Impact factor: 5.250

8.  Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Authors:  M Backonja; A Beydoun; K R Edwards; S L Schwartz; V Fonseca; M Hes; L LaMoreaux; E Garofalo
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

9.  Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.

Authors:  M Rowbotham; N Harden; B Stacey; P Bernstein; L Magnus-Miller
Journal:  JAMA       Date:  1998-12-02       Impact factor: 56.272

10.  Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia.

Authors:  D L Jones; L S Sorkin
Journal:  Brain Res       Date:  1998-11-09       Impact factor: 3.252

View more
  9 in total

1.  Altered somatosensory processing in trigeminal neuralgia.

Authors:  Maria Blatow; Ernst Nennig; Elise Sarpaczki; Julia Reinhardt; Martin Schlieter; Christian Herweh; Dirk Rasche; Volker M Tronnier; Klaus Sartor; Christoph Stippich
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

Review 2.  A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process.

Authors:  Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2017-08-12       Impact factor: 8.989

3.  CNS animal fMRI in pain and analgesia.

Authors:  David Borsook; Lino Becerra
Journal:  Neurosci Biobehav Rev       Date:  2010-11-30       Impact factor: 8.989

Review 4.  Approach to chronic cough: the neuropathic basis for cough hypersensitivity syndrome.

Authors:  Kian Fan Chung
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

5.  Aberrant temporal and spatial brain activity during rest in patients with chronic pain.

Authors:  Sanna Malinen; Nuutti Vartiainen; Yevhen Hlushchuk; Miika Koskinen; Pavan Ramkumar; Nina Forss; Eija Kalso; Riitta Hari
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-22       Impact factor: 11.205

Review 6.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

7.  Multiple sites and actions of gabapentin-induced relief of ongoing experimental neuropathic pain.

Authors:  Kirsty Bannister; Chaoling Qu; Edita Navratilova; Janice Oyarzo; Jennifer Yanhua Xie; Tamara King; Anthony H Dickenson; Frank Porreca
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

8.  Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain.

Authors:  Hsiao-Chun Lin; Yu-Hsin Huang; Tzu-Hao Harry Chao; Wen-Ying Lin; Wei-Zen Sun; Chen-Tung Yen
Journal:  Mol Pain       Date:  2014-09-25       Impact factor: 3.395

9.  Imaging conditioned fear circuitry using awake rodent fMRI.

Authors:  Nichola M Brydges; Heather C Whalley; Maurits A Jansen; Gavin D Merrifield; Emma R Wood; Stephen M Lawrie; Sara-Madge Wynne; Mark Day; Sue Fleetwood-Walker; Douglas Steele; Ian Marshall; Jeremy Hall; Megan C Holmes
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.